Biomea Fusion, Inc. current report, 14 June 2023

Full document

Biomea Fusion, Inc. — Form 8-K Summary

Reporting date: June 14, 2023; filed June 15, 2023. The report covers results of the company’s 2023 Annual Meeting of Stockholders under Item 5.07.

Business Context and Reporting Period

Biomea Fusion, Inc. is a Delaware biotechnology company headquartered in Redwood City, California. Its common stock trades on The Nasdaq Global Market under the symbol BMEA. The filing does not provide operating or financial results for a quarterly or annual reporting period.

Financial and Capital Metrics

  • The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, cash balance, or other financial metrics.
  • No financial guidance or capital-raising information was reported.

Material Corporate Actions

  • Two Class II director nominees were elected to serve until the 2026 Annual Meeting or until their successors are elected and qualified.
  • Rainer (Ramses) Erdtmann received 16,369,686 votes for and 5,798,793 votes withheld.
  • Eric Aguiar, M.D. received 16,248,905 votes for and 5,919,574 votes withheld.
  • There were 4,235,582 broker non-votes on the director election proposal.
  • Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
  • The auditor appointment received 26,375,250 votes for, 7,575 against, and 21,236 abstentions, with no broker non-votes.

Voting Participation

  • Shares entitled to vote: 35,648,288.
  • Shares present or represented by valid proxy: 26,404,061.

Guidance, Risks, and Unusual Items

The filing contains no management outlook, financial guidance, material risk update, contingency, litigation disclosure, or unusual financial item. It is limited to annual-meeting voting results.

Investor Verification Items

  • Confirm the continued composition and terms of the Board’s Class II directors through the 2026 annual meeting.
  • Review subsequent filings for any changes to the board, auditor, or corporate governance structure.
  • Use the company’s periodic reports, rather than this Form 8-K, to verify cash, liquidity, operating results, financing needs, and clinical-development risks.